Please wait





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)




SCHEDULE 13D/A 0001104659-22-052966 0001907614 XXXXXXXX LIVE 3 Ordinary shares, par value USD $0.0001 per share 01/25/2025 false 0001818838 005329107 Adagene, Inc. 4F, Building C14, No. 218, Xinghu Street Suzhou Industrial Park Suzhou, Jiangsu Province F4 215123 Peter Luo 86-512-8777-3632 4F, Building C14, No. 218, Xinghu Street Suzhou Industrial Park Suzhou, Jiangsu Province F4 215123 0001907614 N Peter Luo a PF OO Y X1 3681318.00 0.00 812483.00 126380.00 3681318.00 N 6.07 IN Row 7 and 11 represent (i) 33,401 ordinary shares held by Peter Luo; (ii) 587,415 ordinary shares underlying share options granted to Peter Luo that are vested or will be vested within 60 days of January 25, 2025, (iii) 191,667 ordinary shares held by Great Han Fortune LP for the benefit of Peter Luo, (iv) 4,817 ordinary shares held by Xiaohong She; (v) 98,230 ordinary shares underlying share options granted to Xiaohong She that are vested or will be vested within 60 days of January 25, 2025, (vi) 23,333 ordinary shares held by Great Han Fortune LP for the benefit of XiaohongShe, (vii) total of 1,656,452 ordinary shares (including ordinary shares represented by the ADSs) held by Raymond Tam, JC Xu, Qinghai Zhao and several key employees of the Company, and (viii) total of 1,086,003 share options granted to Raymond Tam, JC Xu, Qinghai Zhao and several key employees that are vested or will be vested within 60 days of January 25, 2025. Row 9 represents (i) 33,401 ordinary shares (including ordinary shares represented by the ADSs) held by Peter Luo; (ii) 587,415 ordinary shares underlying share options granted to Peter Luo that are vested or will be vested within 60 days of January 25, 2025, and (iii) 191,667 ordinary shares held by Great Han Fortune LP for the benefit of Peter Luo. Row 10 represents (i) 4,817 ordinary shares held by Xiaohong She; (ii) 98,230 ordinary shares underlying share options granted to Xiaohong She that are vested or will be vested within 60 days of January 25, 2025, (iii) 23,333 ordinary shares held by Great Han Fortune LP for the benefit of Xiaohong She. Row 13 represents calculation based on (i) 58,886,944 ordinary shares issued and outstanding as of December 31, 2024, as provided by the Issuer and (ii) 1,771,648 ordinary shares underlying share options granted to Peter Luo-Acting-in-Concert-Group that are vested or will be vested within 60 days of January 25, 2025. Y HAN 2020 Irrevocable Trust a PF OO Y CA 9175439.00 0.00 9175439.00 0.00 9175439.00 N 15.58 OO Rows 7, 9 and 11 represents 9,175,439 ordinary shares held by HAN 2020 Irrevocable Trust. The HAN 2020 Irrevocable Trust is a family trust established by Dr. Peter Luo as trustor for the benefits of Dr. Luo's family members, of which North Point Trust Company is the current trustee. Row 13 represents calculation based on 58,886,944 ordinary shares issued and outstanding as of December 31, 2024, as provided by the Issuer. Ordinary shares, par value USD $0.0001 per share Adagene, Inc. 4F, Building C14, No. 218, Xinghu Street Suzhou Industrial Park Suzhou, Jiangsu Province F4 215123 On May 6, 2024, Mr. Luo received 1,108,333 ordinary shares from Great Han Fortune LP for the benefit of Peter Luo, and Xiaohong She received 234,167 ordinary shares from Great Han Fortune LP for the benefit of Xiaohong She. On May 6, 2024, Mr. Luo and Xiaohong She transferred 2,889,074 and 286,365 ordinary shares respectively to HAN 2020 Irrevocable Trust, for estate planning purpose. On December 19, 2024, the trustee of the Han 2020 Irrevocable Trust was changed from Xiaohong She to North Point Trust Company. North Point Trust Company, acting as the independent trustee, exercises all powers of the investment director under the trust. Accordingly, beneficial ownership of the Han 2020 Irrevocable Trust is ceased to be attributed to Xiaohong She or Peter Luo. Due to the operation of the Concert Party Agreement dated December 14, 2020 among members of Peter Luo-Acting-in-Concert-Group, Peter Luo may be deemed to acquire or dispose additional beneficial ownership from time to time due to the acquisition or disposal of beneficial ownership by the members of Peter Luo-Acting-in-Concert-Group. The Reporting Persons, including Mr. Luo, have not otherwise disposed or sold any ordinary shares or ADSs they beneficially owned since the filing of Amendment No.2 of the Schedule 13D on March 1, 2024. The Reporting Persons acquired the ordinary shares reported herein for investment and estate planning purposes, in the ordinary course of business. Other than as disclosed in this Amendment, the Reporting Persons currently do not have any plans or proposals that would result in or relate to any of the transactions or changes listed in Items 4(a) through 4(j) of the Schedule 13D. Mr. Luo is the Chief Executive Officer, President of R&D and the Chairman of the Board of Directors of the Issuer. The Reporting Persons, including members of the Peter Luo-Acting-in-Concert-Group, may acquire additional ordinary shares in the ordinary course of business, including in connection with outstanding options or additional options to be granted by the Issuer to Mr. Luo and/or share repurchase plan established by Mr. Luo in his personal capacity. The information set forth in the cover page for the Reporting Persons is hereby incorporated by reference. See Item 5(a). Other than as discussed in this Amendment, including with respect to ordinary shares underlying options, during the past sixty days prior to the date of this statement, the Reporting Persons have not acquired any shares of the Issuer's Ordinary Shares. No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of ordinary shares of the Issuer owned by the Reporting Persons. Not applicable. On December 14, 2020, Peter Luo, Fangyong (Felix) Du, Ping Ren, Dr. Hua Gong, JC Xu, Qinghai Zhao, Man Kin (Raymond) Tam, Xiaohong (Kristine) She, Yan Li, Guizhong Liu, Alexander Goergen, and, on February 18, 2021, Yu (Albert) Ren) (together, the "Peter Luo-Acting-in-Concert-Group") entered into a concert party agreement (the "Agreement"), pursuant to which the parties agree to (i) always be acting in concert in respect of their respective direct or indirect voting rights at our shareholders' general meetings, (ii) recognize the controlling position of Peter Luo; and (iii) act in concert in accordance with Peter Luo's opinions in respect of the daily operations and management and the major decision-making of the Issuer. Dr. Hua Gong, Yu (Albert) Ren, Fangyong (Felix) Du and Ping Ren are no longer subject to the concert party agreement due to their departure from the Issuer. The HAN 2020 Irrevocable Trust is a family trust established by Dr. Peter Luo as trustor and Xiaohong She as the initial trustee under a trust agreement dated September 28, 2020, for the benefits of Dr. Luo's family members. On December 19, 2024, the trustee of the Han 2020 Irrevocable Trust was changed from Xiaohong She to North Point Trust Company. North Point Trust Company, acting as the independent trustee, exercises all powers of the investment director under the trust. Accordingly, beneficial ownership of the Han 2020 Irrevocable Trust is ceased to be attributed to Xiaohong She or Peter Luo. Peter Luo /s/ Peter Luo Peter Luo 02/19/2025 HAN 2020 Irrevocable Trust /s/ Todd Wiles North Point Trust Company/ Trustee 02/19/2025